Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin

Marc Weiner, William Burman, Chi Cheng Luo, Charles A. Peloquin, Melissa Engle, Stefan Goldberg, Vipin Agarwal, Andrew Vernon

Research output: Contribution to journalArticle

83 Scopus citations

Abstract

Treatment regimens combining moxifloxacin and rifampin for drug-susceptible tuberculosis are being studied intensively. However, rifampin induces enzymes that transport and metabolize moxifloxacin. We evaluated the effect of rifampin and the human multidrug resistance gene (MDR1) C3435T polymorphisms (P-glycoprotein) on moxifloxacin pharmacokinetic parameters. This was a single-center, sequential design study with 16 volunteers in which sampling was performed after four daily oral doses of moxifloxacin (400 mg) and again after 10 days of combined rifampin (600 mg) and moxifloxacin. After daily coadministration of rifampin, the area under the concentration-time curve from 0 to 24 h (AUC0-24) for moxifloxacin decreased 27%. Average bioequivalence between moxifloxacin coadministered with rifampin and moxifloxacin alone was not demonstrated: the ratio of geometric means (RGM) of the moxifloxacin AUC0-24 was 73.3 (90% confidence intervals [CI], 64.3, 83.5) (total P value, 0.87 for two one-sided t tests). Peak moxifloxacin concentrations, however, were equivalent: the RGM of the maximum concentration of the drug in serum was 93.6 (90% CI, 80.2, 109.3) (total P value, 0.049). Concentrations of the sulfate conjugate metabolite of moxifloxacin were increased twofold following rifampin coadministration (AUC0-24, 1.29 versus 2.79 μg·h/ml). Concomitant rifampin administration resulted in a 27% decrease in the mean moxifloxacin AUC0-24 and a marked increase in the AUC0-24 of the microbiologically inactive M1 metabolite. Additional studies are required to understand the clinical significance of the moxifloxacin-rifampin interaction.

Original languageEnglish (US)
Pages (from-to)2861-2866
Number of pages6
JournalAntimicrobial agents and chemotherapy
Volume51
Issue number8
DOIs
StatePublished - Aug 2007

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin'. Together they form a unique fingerprint.

  • Cite this

    Weiner, M., Burman, W., Luo, C. C., Peloquin, C. A., Engle, M., Goldberg, S., Agarwal, V., & Vernon, A. (2007). Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrobial agents and chemotherapy, 51(8), 2861-2866. https://doi.org/10.1128/AAC.01621-06